[go: up one dir, main page]

MX2011011374A - Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma. - Google Patents

Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma.

Info

Publication number
MX2011011374A
MX2011011374A MX2011011374A MX2011011374A MX2011011374A MX 2011011374 A MX2011011374 A MX 2011011374A MX 2011011374 A MX2011011374 A MX 2011011374A MX 2011011374 A MX2011011374 A MX 2011011374A MX 2011011374 A MX2011011374 A MX 2011011374A
Authority
MX
Mexico
Prior art keywords
preparation
pharmaceutical composition
oral pharmaceutical
hydrophilic drug
self micro
Prior art date
Application number
MX2011011374A
Other languages
English (en)
Other versions
MX349014B (es
Inventor
Chang-Shan Hsu
Wei-Hua Hao
Jong-Jing Wang
Tsung-Hsin Lin
Original Assignee
Innopharmax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42992661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011374(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innopharmax Inc filed Critical Innopharmax Inc
Publication of MX2011011374A publication Critical patent/MX2011011374A/es
Publication of MX349014B publication Critical patent/MX349014B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición farmacéutica oral auto-microemulsificante de un fármaco hidrofílico o su sal farmacéuticamente aceptable y su método de preparación. La composición comprende un fármaco hidrofílico tal como bendamustina o gemcitabina, solvente, tensoacitvo y un portador hirofílico, y tiene buena biodisponibilidad y estabilidad. Ese portador hidrofílico es compatible con la solución del fármaco y el tensoactivo.
MX2011011374A 2009-04-27 2010-04-27 Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma. MX349014B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17290109P 2009-04-27 2009-04-27
PCT/CN2010/000577 WO2010124525A1 (zh) 2009-04-27 2010-04-27 亲水性药物之自微乳化医药组合物及其制备

Publications (2)

Publication Number Publication Date
MX2011011374A true MX2011011374A (es) 2012-02-08
MX349014B MX349014B (es) 2017-07-06

Family

ID=42992661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011374A MX349014B (es) 2009-04-27 2010-04-27 Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma.

Country Status (20)

Country Link
US (3) US20100273730A1 (es)
EP (2) EP3045165B1 (es)
JP (1) JP5753157B2 (es)
KR (1) KR101759750B1 (es)
CN (1) CN102427803B (es)
AU (1) AU2010242461B2 (es)
BR (1) BRPI1011764A2 (es)
CA (1) CA2760039C (es)
CO (1) CO6470799A2 (es)
ES (1) ES2831037T3 (es)
IL (1) IL215988A (es)
MX (1) MX349014B (es)
MY (1) MY174001A (es)
NZ (1) NZ596657A (es)
RU (1) RU2532362C2 (es)
SG (1) SG175808A1 (es)
TW (1) TWI461212B (es)
UA (1) UA105042C2 (es)
WO (1) WO2010124525A1 (es)
ZA (1) ZA201108686B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528602B2 (en) 2010-01-28 2020-02-12 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
PL2575784T3 (pl) * 2010-06-02 2019-03-29 Astellas Deutschland Gmbh Doustne postaci dawkowania bendamustyny
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
RS65177B1 (sr) 2012-03-20 2024-03-29 Eagle Pharmaceuticals Inc Formulacije bendamustina
US9000021B2 (en) * 2012-03-20 2015-04-07 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9849115B2 (en) 2013-08-27 2017-12-26 Vasilios Voudouris Bendamustine pharmaceutical compositions
WO2015104720A2 (en) * 2014-01-13 2015-07-16 Hetero Research Foundation Parenteral compositions of bendamustine
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
EP3215128B1 (en) * 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9861629B1 (en) * 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10335405B1 (en) * 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
EP3463298B1 (en) * 2016-06-02 2021-09-01 Innopharmax, Inc. Metronomic oral gemcitabine for cancer therapy
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019051437A1 (en) * 2017-09-11 2019-03-14 Board Of Regents, The University Of Texas System COMPOSITIONS FOR ENHANCED MEDICATION DELIVERY
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂
MX2022010387A (es) * 2020-04-13 2022-09-05 US Nano Food & Drug INC Formulacion basica para inyeccion quimioterapeutica intratumoral.
CN112006986A (zh) * 2020-08-07 2020-12-01 厦门大学 一种维生素e琥珀酸酯聚乙二醇纳米胶束及其制备方法和应用
CN114397381A (zh) * 2021-12-17 2022-04-26 南京农业大学 一种沼液中阿莫西林的提取及含量检测方法
CN120859944A (zh) * 2022-11-22 2025-10-31 中南大学湘雅医院 一种含有拉莫三嗪自微乳组合物的制剂及其应用
US20250195418A1 (en) * 2023-08-21 2025-06-19 Cmpd Licensing, Llc Topical administration to the oral cavity
WO2025238457A1 (en) * 2024-05-13 2025-11-20 Nanda Gargi An oral self-micro-emulsifying pharmaceutical composition of a hydrophilic drug

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1995014037A1 (en) * 1993-11-17 1995-05-26 Ibah, Inc. Transparent liquid for encapsulated drug delivery
CN1173742C (zh) * 1997-12-26 2004-11-03 山之内制药株式会社 缓释药物组合物
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7217735B1 (en) * 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7309696B2 (en) * 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
CA2449856C (en) * 2001-06-15 2009-03-10 Cornerstone Pharmaceuticals Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
US7053076B2 (en) * 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
DE10306724A1 (de) * 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
NZ536294A (en) * 2002-05-03 2005-05-27 Janssen Pharmaceutica Nv Polymeric microemulsions of amphiphilic diblock copolymers
AU2003268087A1 (en) 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
CN1593405A (zh) * 2004-07-09 2005-03-16 沈阳药科大学 一种氟康唑液体型组方及其制剂
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
JPWO2007089043A1 (ja) 2006-02-03 2009-06-25 武田薬品工業株式会社 リポソーム製剤
AU2007224006A1 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
AU2008296971B2 (en) * 2007-09-03 2014-10-02 Nanoshift, Llc Particulate compositions for delivery of poorly soluble drugs

Also Published As

Publication number Publication date
EP3045165B1 (en) 2020-09-23
MX349014B (es) 2017-07-06
TWI461212B (zh) 2014-11-21
US20150196537A1 (en) 2015-07-16
MY174001A (en) 2020-03-03
CO6470799A2 (es) 2012-06-29
ES2831037T3 (es) 2021-06-07
SG175808A1 (en) 2011-12-29
NZ596657A (en) 2014-01-31
CN102427803A (zh) 2012-04-25
EP3045165A3 (en) 2016-09-21
IL215988A0 (en) 2012-01-31
IL215988A (en) 2016-12-29
US20100273730A1 (en) 2010-10-28
WO2010124525A1 (zh) 2010-11-04
RU2532362C2 (ru) 2014-11-10
CN102427803B (zh) 2015-06-10
US20190275006A1 (en) 2019-09-12
EP2425818A4 (en) 2012-10-24
ZA201108686B (en) 2012-08-29
EP2425818A1 (en) 2012-03-07
CA2760039A1 (en) 2010-11-04
HK1165701A1 (en) 2012-10-12
UA105042C2 (uk) 2014-04-10
TW201041597A (en) 2010-12-01
JP2012524820A (ja) 2012-10-18
BRPI1011764A2 (pt) 2016-03-29
EP3045165A2 (en) 2016-07-20
AU2010242461B2 (en) 2016-05-19
RU2011148140A (ru) 2013-06-10
CA2760039C (en) 2017-05-16
KR20120015330A (ko) 2012-02-21
KR101759750B1 (ko) 2017-07-31
JP5753157B2 (ja) 2015-07-22
AU2010242461A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
MX2011011374A (es) Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma.
WO2011012816A3 (fr) Formulation pharmaceutique
WO2009006590A3 (en) Docetaxel process and polymorphs
WO2008131114A3 (en) Pharmaceutical formulations containing lipoic acid derivatives
BRPI0910758A2 (pt) composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto
WO2010117738A3 (en) Solid state forms of sitagliptin salts
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2010092090A3 (en) Novel salts of sitagliptin
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
HUE037742T2 (hu) Szubsztituált azolok, vírusellenes aktív adalék, gyógyszerészeti készítmény, az elõállításukat célzó eljárás és alkalmazásuk
WO2011120904A3 (en) A fast dissolving pharmaceutical composition
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
WO2011120903A3 (en) A fast dissolving pharmaceutical composition
WO2010049449A3 (en) Novel salts of sunitinib
WO2014062838A3 (en) Pkm2 modulators and methods for their use
EP2665464A2 (en) A carrier for oromucosal, especially sublingual administration of physiologically active substances
BR112013013903A2 (pt) preparação farmacêutica aquosa estável pronta para uso de cetrorelix para administração parenteral, processo para a fabricação de uma preparação farmacêutica aquosa estável pronta para uso de cetrorelix para uso de cetrorelix para administração parenteral
WO2012108631A3 (en) Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof
HUE040484T2 (hu) Eljárás (3S,3S')4,4'-diszulfándiilbisz(3-aminobután-1-szulfonsav) elõállítására
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
MX2012007393A (es) Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam.
WO2013062332A3 (ko) 시링가레시놀을 포함하는 혈관 노화 억제용 조성물
MX2012005596A (es) Derivados de difenil azepano como inhibidores de reabsorcion de monoaminas.
WO2009121946A3 (en) Process for the preparation of optically enriched clopidogrel

Legal Events

Date Code Title Description
FG Grant or registration